Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic avenue for managing metabolic disorders. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin release and suppressing glucagon release. GLP-1 peptides demonstrate promising therapeutic efficacy in treating type 2 c